Dr. Adeera Levin presents her talk, “Delaying Progression of Kidney Disease: What’s New and What’s Coming,” as part of BC Renal’s province-wide rounds.
0:05:00 - Introduction
She starts by highlighting statistics on kidney disease as a global heath problem, noting that it is increasing in prevalence as a leading cause of death and also involves steep health care costs. Early identification of kidney disease is a means to reduce associated costs. Importantly, many people who need renal replacement therapies are not receiving them.
0:10:00 - New data and tools
Dr. Levin highlights new tools to improve diagnoses and estimate GFR. She points to some projects that are aimed to better understand the causes of kidney disease (e.g., by the Kidney Precision Medicine Project and NEPTUNE). She discusses novel markers in blood and urine that researchers are exploring (e.g., cell composition, markers of inflammation, T cells, kidney tubular epithelial cells), as well as imaging techniques (e.g., renal MRI as a non-invasive tool). She notes how emerging tools to understand risk factors and prognosis could lead to more tailored treatment plans, patient counselling, and timeliness of decision-making.
0:23:00 - New and emerging treatments
Dr. Levin briefly touches on recent trials that underscore the benefits of SGLT2 inhibitors in kidney patients, which could buy these patients an estimated additional 15 years of life, evidence suggests. Next, Dr. Levin discusses aldosterone, and traditional ways of targeting it (e.g., RAAS) and newer options, (e.g., MR antagonists such as finerenone, aldosterone synthase inhibitors). She notes a new paradigm for kidney care that involves cardiovascular, inflammatory and metabolic changes that cause kidney disease progression, and points to an upcoming trial that will explore a multi-pronged approach to target these various factors. Next, Dr. Levin highlights data and pending trials on GLP-1 (e.g., semaglutide), which can reduce the rate of kidney function decline, before briefly discussing endothelin antagonists in proteinuric renal disease.
0:43:00 - Care and guidelines
Dr. Levin notes that the new KDIGO guidelines will be available in early 2024 and provides a brief overview of the format. She emphasizes special considerations on care of individuals based on their sex and gender, and stage of life. Lastly, Dr. Levin notes the influence of lifestyle (e.g., diet, exercise) on kidney health, and discusses emerging insights on starting and stopping medications.
0:52:00 - Summary and Q&A
Dr. Levin makes some concluding remarks before taking questions from the audience.
Click here to join our mailing list to receive the latest news and information from BC Renal: app.cyberimpac...
26 авг 2024
